BR112015009107A2 - agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo - Google Patents

agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR112015009107A2
BR112015009107A2 BR112015009107A BR112015009107A BR112015009107A2 BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2 BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
growth hormone
receptor agonist
hormone secretagogue
Prior art date
Application number
BR112015009107A
Other languages
English (en)
Portuguese (pt)
Inventor
Furuya Mayumi
Murayama Norihito
Matsuo Tsuyoshi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112015009107A2 publication Critical patent/BR112015009107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
BR112015009107A 2012-10-24 2013-10-23 agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo BR112015009107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Publications (1)

Publication Number Publication Date
BR112015009107A2 true BR112015009107A2 (pt) 2017-11-14

Family

ID=50544716

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009107A BR112015009107A2 (pt) 2012-10-24 2013-10-23 agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo

Country Status (12)

Country Link
US (1) US20150265680A1 (zh)
EP (1) EP2913063B1 (zh)
JP (1) JP6262661B2 (zh)
KR (3) KR102499918B1 (zh)
CN (2) CN104853778A (zh)
AU (1) AU2013335678B2 (zh)
BR (1) BR112015009107A2 (zh)
CA (1) CA2889499C (zh)
HK (1) HK1214152A1 (zh)
IN (1) IN2015DN04172A (zh)
RU (1) RU2655811C2 (zh)
WO (1) WO2014065341A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967355A1 (en) 2014-11-12 2016-05-19 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
JP2022513721A (ja) * 2018-12-06 2022-02-09 バイオジェン・エムエイ・インコーポレイテッド 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質
US11969416B1 (en) 2022-11-03 2024-04-30 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CA2340701C (en) 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers
AU784035B2 (en) * 1999-07-23 2006-01-19 Kenji Kangawa Novel peptides
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US6849597B2 (en) 1999-12-28 2005-02-01 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
DE60128494T2 (de) 2000-06-13 2008-01-17 Zentaris Gmbh Verbindungen zur Stimulation der Sekretion von Wachstumshormonen
CA2472235C (en) 2002-04-11 2012-05-22 Daiichi Suntory Pharma Co., Ltd. A method for producing a modified peptide
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
JPWO2007046347A1 (ja) * 2005-10-18 2009-04-23 小野薬品工業株式会社 筋萎縮性側索硬化症患者の運動神経保護用医薬
LT2489733T (lt) 2006-06-07 2019-05-27 Genzyme Corporation Šoninės amiotrofinės sklerozės ir kitų nugaros smegenų sutrikimų genų terapija
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
KR101273187B1 (ko) * 2008-04-03 2013-06-17 에프. 호프만-라 로슈 아게 신경근 장애의 치료를 위한 폴리(에틸렌글리콜)(ｐｅｇ)-부착된 ｉｇｆ-ｉ 변이체의 용도

Also Published As

Publication number Publication date
JPWO2014065341A1 (ja) 2016-09-08
RU2015119472A (ru) 2016-12-20
IN2015DN04172A (zh) 2015-10-16
KR20150070180A (ko) 2015-06-24
CA2889499A1 (en) 2014-05-01
KR20220051418A (ko) 2022-04-26
WO2014065341A1 (ja) 2014-05-01
KR20200108494A (ko) 2020-09-18
HK1214152A1 (zh) 2016-07-22
EP2913063B1 (en) 2019-09-11
CA2889499C (en) 2019-09-10
CN104853778A (zh) 2015-08-19
US20150265680A1 (en) 2015-09-24
AU2013335678A1 (en) 2015-05-21
RU2655811C2 (ru) 2018-05-29
CN110354265A (zh) 2019-10-22
EP2913063A4 (en) 2016-07-20
JP6262661B2 (ja) 2018-01-17
EP2913063A1 (en) 2015-09-02
AU2013335678B2 (en) 2017-10-26
KR102499918B1 (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
HK1251185A1 (zh) 用於治療皮膚病的甲酰基肽受體2的激動劑的用途
BR112015010314A2 (pt) composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios
EP3535016A4 (en) DEVICE FOR PERCUTANEOUSLY DELIVERING THERAPEUTIC AGENTS, AND METHOD OF USING SAME
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2014000802A1 (es) Proceso para la preparacion de estetrol, util para terapia de reemplazo hormonal y la anticoncepcion.
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
HK1200187A1 (zh) 人源化抗上皮調節蛋白抗體和含有該抗體作為有效成分的癌症治療藥
HK1223583A1 (zh) 透皮釋放活性物質的系統
PL3053916T3 (pl) Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanie
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
EP2990040A4 (en) Therapeutic agent for eyeground disease
GB201312344D0 (en) Liposomal drug delivery system for bone cements
BR112015009107A2 (pt) agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
PL2862565T3 (pl) Farmaceutyczna kompozycja ibuprofenu i tramadolu do zastosowania w okulistyce
EP3019130A4 (en) DRUG-PROLONGED TRANSDERMAL RELEASE KIT USING LIQUID OR SEMI-SOLID COMPOSITIONS AND METHOD OF USING THE SAME
EP2820021A4 (en) GONADOTROPIN RELEASING HORMONIC RECEPTOR ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
PL3315117T3 (pl) Kompozycja do higieny jamy ustnej dostarczająca środki aktywne do pielęgnacji jamy ustnej
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
BR112016013776A2 (pt) Composto derivado do ácido 3-(5-cloro-2-oxibenzo[d]oxazol-3(2h)-il)propanoico ou um sal deste, uso terapêutico do mesmo e composição farmacêutica compreendendo o referido composto
BR112012029824A2 (pt) métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.